Is CHE a buy according to AI stock analysis?

CHE AI stock analysis does not label Chemed as an automatic buy, though it is a well-managed holding company. The business quality is good with defensible cash flows, but the stock trades near 25x TTM earnings and is approaching 52-week highs, so a buyer should assess their conviction in hospice volume growth, Roto-Rooter stability, and the CEO succession plan.

What is the CHE AI stock forecast?

The CHE AI stock forecast uses scenarios, not a guaranteed target. Around the $488.59 cutoff price, the bullish scenario is roughly $600 to $775, the base scenario is roughly $450 to $545, and the bearish scenario is roughly $300 to $400, depending on hospice census growth, Medicare policy, Roto-Rooter demand, and valuation multiples.

What technical levels matter for CHE?

The key CHE technical levels are the $493 to $494 resistance zone, the $483 to $477 near-support zone, and the $472 to $444 deeper support area. A close below $477 would weaken near-term momentum, while a break above $494 could open a move toward $500.

Can AI predict CHE stock price?

No, AI cannot reliably predict stock prices. AI can organize filings, market data, valuation math, technical levels, and risk scenarios, but CHE can still move sharply after earnings, Medicare regulatory news, DOJ developments, or changes in the broader healthcare sector.

How should I use this CHE AI trading strategy?

Use this CHE AI trading strategy as a research checklist, not a personal instruction. Confirm live price, volume, moving averages, earnings timing, position size, stop level, and portfolio risk before making any trade.

What is the biggest risk in Chemed stock analysis?

The biggest risk in Chemed stock analysis is regulatory dependency: about half of revenue comes from Medicare-reimbursed hospice care. A significant change in hospice reimbursement policy would directly impact VITAS revenue and margins. CEO succession at both the corporate and VITAS level also introduces execution risk.

Chemed Corporation research snapshot

CHE AI Stock Analysis

CHE AI stock analysis currently reads Chemed Corporation as a defensive healthcare and services holding company with two high-quality subsidiaries: VITAS Healthcare and Roto-Rooter. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $488.59, market capitalization was about $6.49 billion, and the main question was whether hospice volume growth, plumbing services demand, and solid cash generation can sustain a mid-20s earnings multiple. This is informational research and not investment advice.

Current price

$488.59

Market cap

$6.49 billion

AI score

72 / 100

Rating

Good business with moderate margin of safety

Trend status

Strong uptrend approaching 52-week highs

Data cutoff (updated weekly)

July 12, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: B-level information richness. Chemed has a long public history and good data availability through SEC filings, but analyst coverage is limited to 2-3 firms. Data is sufficient for fundamental analysis but thinner than large-cap healthcare peers.
bias Check: The main AI bias risk is consensus anchoring from the small analyst pool. This page separates filing-backed facts from scenario judgments and explicitly identifies data gaps from limited coverage.
ai Confidence: Medium-high data confidence
investment Certainty: Medium. Chemed is a well-managed holding company with solid cash flow, but the holding company structure makes it harder to model than a pure-play business, and valuation depends on continued organic growth at both subsidiaries.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Chemed owns two essential-service businesses: VITAS (largest US hospice provider) and Roto-Rooter (leading plumbing/drain services). Both have recurring demand characteristics.	High
Moat	Roto-Rooter has brand recognition and scale in fragmented plumbing services. VITAS has economies of scale in hospice operations, but switching costs are low and regulation is significant.	Medium-high
Management	CEO Kevin McNamara has led Chemed since 1999 with a disciplined capital allocation record. VITAS CEO Joel Wherley appointed July 2025 is a newer variable.	Medium-high
Financial trend	TTM revenue of about $2.54 billion and TTM net income of about $265 million show steady growth. Revenue from the latest four quarters grew roughly 7-8% year-over-year.	High
Valuation	CHE trades near 25x TTM earnings and about 20x TTM free cash flow, which is reasonable for the defensive growth profile but offers only a moderate margin of safety.	Medium
Technical trend	CHE is in a strong uptrend, up 26.6% in 3 months and approaching 52-week highs around $493.47. Momentum is positive but the stock is technically extended.	Medium-high
Risk level	Key risks are hospice regulatory changes (Medicare reimbursement), DOJ settlement legacy, VITAS CEO transition, Roto-Rooter cyclical exposure, and succession risk at Chemed corporate.	Medium-high
AI confidence	Medium-high confidence for the business map, latest filings, and market cap math. Lower confidence for projection accuracy due to limited analyst coverage and holding company complexity.	Medium-high data confidence
Investment certainty	Medium certainty. CHE is a well-run company with defensible businesses, but the limited analyst coverage, holding company structure, and leadership transition create uncertainty.	Medium

CHE AI stock forecast

CHE AI Stock Forecast Scenarios

The CHE AI stock forecast uses scenario ranges around the $488.59 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained hospice census growth, stable Medicare reimbursement, and Roto-Rooter margin recovery. The base case assumes mid-single-digit organic growth with moderate multiple compression. The bearish case assumes regulatory headwinds or operational issues at either subsidiary.

Bullish case

$600 to $775

More likely if VITAS grows patient census above industry trends, regulatory environment remains favorable, Roto-Rooter expands margins, and the market rewards CHE with a 28x forward PE multiple.

Base case

$450 to $545

More likely if earnings grow at a mid-single-digit pace, cash generation continues, and CHE trades near a 22x PE multiple consistent with its defensive healthcare profile.

Bearish case

$300 to $400

More likely if Medicare hospice reimbursement faces cuts, VITAS CEO transition disrupts operations, Roto-Rooter experiences a demand slowdown, and the market re-rates CHE toward a 16x PE.

CHE AI technical analysis

CHE AI Technical Analysis

CHE AI technical analysis starts from the $488.59 July 10 close used for this July 12 static page. Public technical sources showed CHE in a strong uptrend, with the stock up 26.6% over 3 months and approaching the 52-week high at $493.47. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.

Level	Value	Why it matters
Current price	$488.59	Latest verified close used for this page as of the July 12, 2026 data cutoff.
Near resistance	$493 to $494	The 52-week high zone. A breakout above this level would open the path toward $500 and the next resistance area.
Secondary resistance	$499 to $505	The next resistance zone reported by Barchart turning points. Requires volume confirmation to sustain above $494.
Near support	$483 to $477	The first support zone from recent trading range. A pullback to this area would be normal in an uptrend.
Secondary support	$472 to $444	Deeper support zone from the 61.8% Fibonacci retracement level around $444. A break below $472 would weaken the near-term trend.
50-day moving average	Approaching $450 area	The 50-day MA likely sits in the $440-$460 range given the strong 3-month upward move. Public sources should be checked for the exact level.
200-day moving average	Approaching $420 area	The 200-day MA is well below the current price, confirming the long-term uptrend. Public sources should be checked for the exact level.
Momentum	RSI near overbought	Barchart reported RSI just crossed below 70% from overbought territory. Momentum indicators suggest the stock may be due for consolidation.
Volume	About 143,000 shares on Jul 10	Volume was below the 214,000 average, suggesting the recent advance lacks strong institutional participation.
Beta	0.52	CHE has very low market correlation. It tends to hold up better in downturns but may lag in strong bull markets.
Invalidation	Close below $472, then $444	A close below the first support zone weakens the near-term setup. A break below the Fibonacci 61.8% level challenges the trend.

CHE AI trading strategy

CHE AI Trading Strategy Framework

The CHE AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.

Trend-following setup

Look for CHE to break above the $493-$494 52-week high zone with above-average volume and hold above $494 to confirm trend continuation.

A failed breakout or daily close below $483 should reduce confidence. Position sizing should account for the low beta and below-average liquidity.

Mean-reversion setup

If CHE pulls back toward $472-$477 without a thesis break, evaluate whether the pullback is driven by profit-taking or fundamental concerns. Use upcoming earnings as a catalyst.

Define maximum loss based on portfolio risk. CHE has low volatility, so position size may need to be larger to achieve meaningful exposure.

Fundamental monitor

Track quarterly hospice census trends, Medicare reimbursement policy, Roto-Rooter revenue and margins, cash flow, and management commentary from earnings calls.

Lower the rating if hospice volumes decline for two consecutive quarters or if Roto-Rooter margins compress due to inflation or competition.

Investment research summary

Four-master Research Compression

Business essence

Chemed operates two essential-service businesses. VITAS provides end-of-life hospice and palliative care with about 22,000 average daily census. Roto-Rooter provides plumbing, drain cleaning, and water restoration services across North America.

Moat

Roto-Rooter benefits from strong brand recognition and a national service network in a fragmented industry. VITAS has scale advantages in hospice operations but faces low switching costs and Medicare reimbursement dependency.

Munger risk inversion

The thesis can fail if Medicare hospice reimbursement is significantly cut, VITAS loses market share or faces regulatory penalties, Roto-Rooter suffers from a housing or remodeling downturn, or the CEO succession process leads to capital allocation mistakes.

Management

CEO Kevin McNamara has been at the helm since 1999, overseeing consistent cash generation and disciplined capital allocation. The appointment of Joel Wherley as VITAS CEO in July 2025 is a monitor item, as the new leadership maintains operational continuity.

Industry trend

Hospice care benefits from favorable demographic trends with the aging US population. Plumbing services are partially tied to housing turnover and remodeling activity but also benefit from recurring maintenance demand.

Valuation and margin of safety

At roughly 25x TTM earnings and 20x TTM free cash flow, CHE trades at a moderate premium to the broad market but at a discount to high-growth healthcare peers. The margin of safety depends on continued organic growth and stable regulatory conditions.

Source-backed data

CHE Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
CHE price	$488.59 close on July 10, 2026	Barchart and Google Finance quote snapshots	July 12, 2026
Market capitalization	$6.49 billion, verified as $488.59 x 13,274,000 shares	financial_rigor.py market cap verification, Barchart, and Google Finance	July 12, 2026
TTM revenue	About $2.54 billion	Barchart and Google Finance Q1 FY2026 financial data	July 12, 2026
TTM net income	About $265 million	Barchart fundamentals and Google Finance earnings data	July 12, 2026
TTM earnings per share	$19.69	Barchart fundamentals	July 12, 2026
Q1 FY2026 revenue	$657.51 million	Google Finance earnings summary	July 12, 2026
Q1 FY2026 EPS	$5.65 (beat estimate of $5.30)	Google Finance earnings data	July 12, 2026
Cash from operations	TTM CFO not directly reported; annual CFO typically $300-$350M (est.)	SEC filings and Barchart fundamentals	July 12, 2026
Dividend	$2.40 annual (0.49% yield), paid quarterly at $0.60	Barchart and Google Finance dividend data	July 12, 2026
P/E and FCF valuation	24.81x TTM PE, 19.89x P/FCF, 5.03% FCF yield from financial_rigor.py	financial_rigor.py valuation verification	July 12, 2026
Three-scenario valuation	Bull $775 (28x), Base $546 (22x), Bear $344 (16x) from financial_rigor.py	financial_rigor.py three-scenario model	July 12, 2026

Frequently Asked Questions

Read the NVDA AI stock analysis View GOOGL AI stock forecast Explore AI Stock Picker Generate an AI trading strategy

This CHE AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.